The state’s top lawyer just filled a key gap in Washington’s campaign finance team. Matt Segal, a former judge and lawyer, now sits on the Public Disclosure Commission. His appointment came after months of criticism over empty seats on the panel. Critics say delays hurt the group’s ability to do its
Federal officials are preparing for a major shift in how marijuana is treated under U. S. law, with changes expected as soon as this week. If approved, this would be the biggest update to marijuana policy in years, making it easier for scientists to study the drug's possible benefits. The push for
The tech giant Dell Technologies has been climbing the stock market ladder, hitting new peaks that have traders buzzing. Over the past year, its shares have jumped almost 160%, and analysts keep a strong “Buy” stance. A recent scan of market data flagged Dell as one of the top performers, thanks to
A billionaire who made his money betting on markets now warns that sports prediction apps can hook young men fast. These platforms let users place bets in seconds through their phones, often linking directly to bank accounts. Unlike older gambling styles, there’s no waiting in line or handing over c
A former senior diplomat says he felt “continuous pressure” from the Prime Minister’s team to hurry up on appointing a new U. S. ambassador, adding fuel to the debate that could threaten the leader’s position. The controversy centers on Labour veteran Peter Mandelson, whose past ties to a convict
A U. S. firm that helped the Trump team secure minerals from the Democratic Republic of Congo has been found to exaggerate its experience in mining. The company, called Virtus Minerals, bought a set of mines from Chemaf for thirty million dollars in March. On its website it claimed to run a copper a
Ark’s chief, Cathie Wood, has lowered her long‑term price forecast for Bitcoin, even as the firm shuffles its crypto‑related holdings. The company sold portions of Circle and Bullish, which together make up less than 1 % of its portfolio. Instead of cashing out, Ark used the money to buy more
Pharmaceutical giant Eli Lilly just dropped $3. 25 billion upfront on a startup called Kelonia Therapeutics, with the potential to pay $7 billion total if everything goes right. The big idea? A treatment that turns your own immune cells into cancer fighters without the usual lab work. Instead of yan
Micron’s stock took a sharp tumble recently, leaving investors scratching their heads. The company, a major player in computer memory chips, has seen its value swing wildly before. But this time, some analysts warn the bounce-back might not happen—at least not quickly. The phrase "dead cats don’t bo
At sixty, Teddy Sheringham has impressive credentials in football. With over fifty caps for England and trophies from top clubs, he’s seen legends rise and fall in the game. Yet one memory still frustrates him decades later—his first meeting with Glenn Hoddle, the midfield genius he once admired. A
